JP7667569B2 - 組換えラブリシン、並びにそれを使用するための組成物及び方法 - Google Patents

組換えラブリシン、並びにそれを使用するための組成物及び方法 Download PDF

Info

Publication number
JP7667569B2
JP7667569B2 JP2021540811A JP2021540811A JP7667569B2 JP 7667569 B2 JP7667569 B2 JP 7667569B2 JP 2021540811 A JP2021540811 A JP 2021540811A JP 2021540811 A JP2021540811 A JP 2021540811A JP 7667569 B2 JP7667569 B2 JP 7667569B2
Authority
JP
Japan
Prior art keywords
cells
mucin
sequence
cell
muc1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021540811A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522965A5 (https=
JP2022522965A (ja
Inventor
パージェック，マシュー
リエジンク，ハイディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of JP2022522965A publication Critical patent/JP2022522965A/ja
Publication of JP2022522965A5 publication Critical patent/JP2022522965A5/ja
Application granted granted Critical
Publication of JP7667569B2 publication Critical patent/JP7667569B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2101/00—Chemical composition of materials used in disinfecting, sterilising or deodorising
    • A61L2101/32—Organic compounds
    • A61L2101/46—Macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021540811A 2019-01-15 2020-01-15 組換えラブリシン、並びにそれを使用するための組成物及び方法 Active JP7667569B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962792660P 2019-01-15 2019-01-15
US62/792,660 2019-01-15
PCT/US2020/013752 WO2020150396A1 (en) 2019-01-15 2020-01-15 Recombinant lubricins, and compositions and methods for using the same

Publications (3)

Publication Number Publication Date
JP2022522965A JP2022522965A (ja) 2022-04-21
JP2022522965A5 JP2022522965A5 (https=) 2023-01-20
JP7667569B2 true JP7667569B2 (ja) 2025-04-23

Family

ID=71614494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021540811A Active JP7667569B2 (ja) 2019-01-15 2020-01-15 組換えラブリシン、並びにそれを使用するための組成物及び方法

Country Status (5)

Country Link
US (2) US20220127319A1 (https=)
EP (1) EP3911355A4 (https=)
JP (1) JP7667569B2 (https=)
CN (2) CN113573724B (https=)
WO (2) WO2020150390A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109735434B (zh) * 2016-09-14 2022-09-23 四川蓝光英诺生物科技股份有限公司 人工组织前体及制备其的方法
JP7667569B2 (ja) * 2019-01-15 2025-04-23 コーネル ユニバーシティー 組換えラブリシン、並びにそれを使用するための組成物及び方法
CN114107437A (zh) * 2021-11-30 2022-03-01 南通大学 一种基于荧光素酶亚基互补的主蛋白酶抑制剂活性检测系统及在药物筛选中的应用
CN115144303B (zh) * 2022-08-01 2025-05-16 中国科学院自动化研究所 基于磁粒子布朗弛豫的细胞质粘度检测方法及应用
CN117106024B (zh) * 2022-10-21 2024-05-24 南京市妇幼保健院 一种人血清多肽agdmp1及其在改善胰岛素抵抗中的应用
WO2025166171A1 (en) * 2024-01-31 2025-08-07 Cornell University Manufacturing and bioprocessing of multispecies biolubricants

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502122A (ja) 2003-08-14 2007-02-08 ワイス 組換えルブリシン分子およびその使用
WO2011019963A2 (en) 2009-08-13 2011-02-17 Singularis, Inc. Prg4 treatment for interstitial cystitis
JP2011519949A (ja) 2008-05-07 2011-07-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼の境界潤滑を増加させるための、眼科治療の装置、及び、その使用方法、
US20170198263A1 (en) 2016-01-13 2017-07-13 Merial Inc. Recombinant AAV Vectors Expressing Osteoprotective genes, including HAS2 and Lubricin, useful in the Treatment of Osteoarthritis and Related Joint Conditions in Mammals
WO2017165674A1 (en) 2016-03-23 2017-09-28 International Aids Vaccine Initiative Immunogenic trimers
WO2018006005A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
JP2018505867A (ja) 2015-01-26 2018-03-01 ルブリス，エルエルシー． 抗炎症剤としてのｐｒｇ４の使用
JP2018515534A (ja) 2015-05-19 2018-06-14 ルブリス，エルエルシー． 動体視力および高次収差を改善するためのｐｒｇ４の使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309760B2 (en) * 2001-04-17 2007-12-18 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
US20060173171A1 (en) * 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
CA2618791C (en) * 2005-08-12 2014-05-13 Riken Novel mucin-type glycoprotein and use thereof
WO2008133928A2 (en) * 2007-04-27 2008-11-06 The Gi Company, Inc. Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
US20140187474A1 (en) * 2011-02-16 2014-07-03 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic use of mucin glycans
WO2013151665A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US20150010606A1 (en) * 2013-07-08 2015-01-08 Arthrex, Inc. Intra-articular injection and implant attachment of molecule consisting of lubricin and extracellular superoxide dismutase or hyaluronic acid and extracellular superoxide dismutase
US20180125926A1 (en) * 2013-09-25 2018-05-10 Axcella Health Inc. Compositions and Formulations and Methods of Production and Use Thereof
WO2015060935A1 (en) 2013-10-22 2015-04-30 Lubris, Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
AU2014354859B2 (en) * 2013-11-26 2020-04-09 Lubris Llc Compositions and methods for inhibiting intercellular interactions
US20160280767A1 (en) * 2015-03-23 2016-09-29 Lonza Ltd. Methods for controlling protein glycosylation
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
CN109055426B (zh) * 2018-08-06 2021-06-25 智享生物(苏州)有限公司 一种在中华仓鼠卵巢细胞中表达生产类人润滑素的方法
JP7667569B2 (ja) * 2019-01-15 2025-04-23 コーネル ユニバーシティー 組換えラブリシン、並びにそれを使用するための組成物及び方法

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502122A (ja) 2003-08-14 2007-02-08 ワイス 組換えルブリシン分子およびその使用
JP2011519949A (ja) 2008-05-07 2011-07-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼の境界潤滑を増加させるための、眼科治療の装置、及び、その使用方法、
JP2011520812A (ja) 2008-05-07 2011-07-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼の表面の潤滑性の治療的調節
WO2011019963A2 (en) 2009-08-13 2011-02-17 Singularis, Inc. Prg4 treatment for interstitial cystitis
JP2018505867A (ja) 2015-01-26 2018-03-01 ルブリス，エルエルシー． 抗炎症剤としてのｐｒｇ４の使用
JP2018515534A (ja) 2015-05-19 2018-06-14 ルブリス，エルエルシー． 動体視力および高次収差を改善するためのｐｒｇ４の使用
US20170198263A1 (en) 2016-01-13 2017-07-13 Merial Inc. Recombinant AAV Vectors Expressing Osteoprotective genes, including HAS2 and Lubricin, useful in the Treatment of Osteoarthritis and Related Joint Conditions in Mammals
WO2017165674A1 (en) 2016-03-23 2017-09-28 International Aids Vaccine Initiative Immunogenic trimers
WO2018006005A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
David K. Rhee et al.，The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth，The Journal of Clinical Investigation，2005年03月，Vol.115, No.3，p.622-631
Equus caballus (Horse)，UniProtKB，F6VTD3，2011年07月27日，2023年11月28日検索,インターネット,https://rest.uniprot.org/unisave/F6VTD3?format=txt&versions=1
PRG4 isoform 6，EMBL，2018年03月28日，PRG4 isoform 6 {ECO:0000313|EMBL:PNJ53749.1},A0A2J8V8A7,[online], UniProtKB. 2018年3月28日掲載, 2023年11月22日検索,インターネット,https://rest.uniprot.org/unisave/A0A2J8V8A7?format=txt&versions=1
quus caballus (Horse)，UniProtKB，F6VTD3，2011年07月27日，2023年11月28日検索,インターネット,https://rest.uniprot.org/unisave/F6VTD3?format=txt&versions=1

Also Published As

Publication number Publication date
US20220127319A1 (en) 2022-04-28
CN113573724A (zh) 2021-10-29
CN113905753A (zh) 2022-01-07
US12304934B2 (en) 2025-05-20
CN113573724B (zh) 2025-12-19
JP2022522965A (ja) 2022-04-21
EP3911355A1 (en) 2021-11-24
EP3911355A4 (en) 2022-06-01
WO2020150390A1 (en) 2020-07-23
US20220127318A1 (en) 2022-04-28
WO2020150396A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
JP7667569B2 (ja) 組換えラブリシン、並びにそれを使用するための組成物及び方法
US12102691B2 (en) Methods for efficient delivery of therapeutic molecules in vitro and in vivo
JP5801293B2 (ja) 血清アミロイドｐ誘導体並びに同誘導体の製造及び使用
CN103068971B (zh) 重编程癌细胞
Fatma et al. Heparin’s roles in stabilizing, potentiating, and transporting LEDGF into the nucleus
Ohno-Jinno et al. Versican and fibrillin-1 form a major hyaluronan-binding complex in the ciliary body
JP2011509966A (ja) 抗菌組成物
US11485762B2 (en) Compositions and methods for inhibition of L-plastin activity in osteoclasts to reduce bone loss
Robinson et al. Structural aspects of molecular recognition in the immune system. Part II: Pattern recognition receptors (IUPAC Technical Report)
EP3728286B1 (en) Engineered o-glycosylation in recombinant polypeptides and uses thereof
Gupta et al. Mannose receptor family: R-type lectins
Shurer The Biophysical Role of the Cellular Glycocalyx: Engineering Glycoproteins to Control Cell-Surface Properties
US20260055211A1 (en) Glycoengineered polypeptides targeting anti-neutrophil autoantibodies and uses thereof
Hromada-Judycka et al. Diacylglycerol kinase-ε is required for the formation of GPI-anchored CD14 and modulates the LPS-induced proinflammatory responses of macrophages
HK40063235B (zh) 用於治疗关节炎的hla-dr/cii肽复合体
HK40064159B (zh) Mhc ii/cii肽复合体的产生
Scheiner-Bobis et al. marine drugs MDPI
Gouizi Prodecorin processing by tolloids and interaction with collagen at the intracellular level
WO2025024729A9 (en) Novel chitosan-il-36ra conjugates for adjustable, sustained release and tissue distribution
Restuccia Glycosylated Peptide Nanofibers as Tools to Elucidate Multivalent Carbohydrate Structure-Function Relationships
Goodstone Cellular Responses to Components of the Extracellular Matrix of Human Articular Cartilage in Patients With Rheumatoid Arthritis
Oldberg Biological functions of iduronic acid in chondroitin/dermatan sulfate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250404

R150 Certificate of patent or registration of utility model

Ref document number: 7667569

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150